I don't know about you but at the moment I'm reading quite a bit of positivity in the HC threads amongst the junior biotechs.
2018 could be a stella year for the 'Juniors' and firmly expecting that NEU will lead the charge but the likes of PNV, PYC and AHZ to be swept along in their own unfolding stories, commercially for PNV and AHZ and in further research collaborations for PYC.
PNV is going to be a cracking success 12 months from here...following David Williams (PNV, MVP) and Richard Treagus (NEU, BTC) and what they might do next is, well, you could do a lot worse (and I have)...
